Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease

Abstract: Epstein-Barr virus (EBV)–associated primary central nervous system lymphoproliferative diseases (EBV+PCNSL) are aggressive conditions with poor prognoses. We previously reported durable responses in patients with PCNSL who were treated with the antivirals ganciclovir and azidothymidine, pl...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autori principali:	Christoph Weigel, Haley L. Klimaszewski, Fode Tounkara, Selamawit Addissie, Sarah Schlotter, Betsy Pray, James P. Dugan, Bradley M. Haverkos, Lynda Villagomez, Mark Lustberg, Pierluigi Porcu, Timothy Voorhees, Richard F. Ambinder, Shannon C. Kenney, Joyce Fingeroth, Henri-Jacques Delecluse, Michael A. Caligiuri, Lapo Alinari, Ginny Bumgardner, Christopher C. Oakes, Robert A. Baiocchi
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2026-05-01
Serie:	Blood Neoplasia
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2950328026000117
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease

Documenti analoghi